» Articles » PMID: 17355265

ADAMs in Cancer Cell Proliferation and Progression

Overview
Journal Cancer Sci
Specialty Oncology
Date 2007 Mar 16
PMID 17355265
Citations 225
Authors
Affiliations
Soon will be listed here.
Abstract

A disintegrin and metalloproteinases (ADAMs) are a new gene family of proteins with sequence similarity to the reprolysin family of snake venomases that share the metalloproteinase domain with matrix metalloproteinases (MMPs). They are structurally classified into two groups: the membrane-anchored ADAM and ADAM with thrombospondin motifs (ADAMTS). These molecules are involved in various biological events such as cell adhesion, cell fusion, cell migration, membrane protein shedding and proteolysis. Studies on the biochemical characteristics and biological functions of ADAMs are in progress, and accumulated lines of evidence have shown that some ADAMs are expressed in malignant tumors and participate in the pathology of cancers. The activities of ADAMs are regulated by gene expression, intracytoplasmic and pericellular regulation, activation of the zymogens and inhibition of activities by inhibitors. Many ADAM species, including ADAM8, ADAM9, ADAM10, ADAM12, ADAM15, ADAM17, ADAM19, ADAM28, ADAMTS1, ADAMTS4 and ADAMTS5, are expressed in human malignant tumors. Many of them are involved in the regulation of growth factor activities and integrin functions, leading to promotion of cell growth and invasion, although the precise mechanisms of these are not clear at the present time. In this article, we review recent information about ADAM family members and their implications for cancer cell proliferation and progression.

Citing Articles

A disintegrin and metallopeptidase domain (ADAM) 12, ADAM 17 mRNA and ADAM10 protein hold potential as biomarkers for detection of early gastric cancer.

Oh S, Lee S, Jin H, Choi S, Cha C, Lee J Sci Rep. 2025; 15(1):763.

PMID: 39755747 PMC: 11700123. DOI: 10.1038/s41598-024-84237-y.


Repurposing raltegravir for reducing inflammation and treating cancer: a bioinformatics analysis.

Nikfarjam Z, Rakhshi R, Zargari F, Aalikhani M, Hasan-Abad A, Bazi Z Sci Rep. 2024; 14(1):30349.

PMID: 39639095 PMC: 11621354. DOI: 10.1038/s41598-024-82065-8.


Genes Related to Motility in an Ionizing Radiation and Estrogen Breast Cancer Model.

Koning T, Calaf G Biology (Basel). 2024; 13(11).

PMID: 39596804 PMC: 11591951. DOI: 10.3390/biology13110849.


Role of long non‑coding RNA leucine‑rich repeat containing 75 A‑antisense RNA1 in the invasion and progression of renal cell carcinoma.

Tokunaga T, Hirata H, Hitaka Y, Fujii N, Kobayashi K, Hayano T Oncol Rep. 2024; 53(1).

PMID: 39575481 PMC: 11603548. DOI: 10.3892/or.2024.8844.


Deciphering the oncogenic potential of ADAM9 in hepatocellular carcinoma through bioinformatics and experimental approaches.

Jiang L, Huang W, Cao M, Jiang Y, Li S, Li M Sci Rep. 2024; 14(1):26432.

PMID: 39488509 PMC: 11531474. DOI: 10.1038/s41598-024-74650-8.


References
1.
Soond S, Everson B, Riches D, Murphy G . ERK-mediated phosphorylation of Thr735 in TNFalpha-converting enzyme and its potential role in TACE protein trafficking. J Cell Sci. 2005; 118(Pt 11):2371-80. DOI: 10.1242/jcs.02357. View

2.
Seals D, Courtneidge S . The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 2003; 17(1):7-30. DOI: 10.1101/gad.1039703. View

3.
Carl-McGrath S, Lendeckel U, Ebert M, Roessner A, Rocken C . The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol. 2004; 26(1):17-24. View

4.
Fogel M, Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Smirnov A . L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet. 2003; 362(9387):869-75. DOI: 10.1016/S0140-6736(03)14342-5. View

5.
Mochizuki S, Shimoda M, Shiomi T, Fujii Y, Okada Y . ADAM28 is activated by MMP-7 (matrilysin-1) and cleaves insulin-like growth factor binding protein-3. Biochem Biophys Res Commun. 2004; 315(1):79-84. DOI: 10.1016/j.bbrc.2004.01.022. View